MedPath

Tri-Lo-Sprintec

These highlights do not include all the information needed to use TRI-LO-SPRINTEC safely and effectively. See full prescribing information for TRI-LO-SPRINTEC.TRI-LO-SPRINTEC (norgestimate/ethinyl estradiol) tablets for oral useInitial U.S. Approval: 1989

Approved
Approval ID

9f96a0fb-21e2-40af-a33c-cf0984fe2550

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 4, 2023

Manufacturers
FDA

Preferred Pharmaceuticals Inc.

DUNS: 791119022

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Norgestimate and Ethinyl Estradiol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68788-7036
Application NumberANDA076784
Product Classification
M
Marketing Category
C73584
G
Generic Name
Norgestimate and Ethinyl Estradiol
Product Specifications
Effective DateOctober 4, 2023
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tri-Lo-Sprintec - FDA Drug Approval Details